Cerramos nuestra participación en #SEC25 con la comunicación "Importancia de colesterol HDL y lipoproteina (a) en el perfil de riesgo cardiovascular del paciente
con síndrome coronario agudo recurrente", que presenta @franbuendia97@J_M_Andreu@ameseguer97@PatonRubio@SMurCardio
ATHEROGENIC RESPONSIBILITY OF LIPOPROTEIN (a) AND OTHER APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS IN ACUTE CORONARY SYNDROME. - Atherosclerosis https://t.co/UYgOf6alU5
Atherosclerosis publishes our study (Cardiology & Clinical Lab, Hospital St. Lucía @area2Cartagena)
"Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in acute coronary syndrome" @franbuendia97@J_M_Andreu@ameseguer97@SMurCardio
.@ameseguer97: El estudio AQUATIC, primer ensayo aleatorizado y doble ciego en este campo, aclara la duda existente en el balance entre el riesgo hemorrágico y aterotrombótico: menos es más". #BlogSEC@jovenesSEC https://t.co/OaT1cdhTxA
The AQUATIC trial may be the most definitive trial of #ESCCOngress
The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots.
MACE worse, Death worse, Bleeding way worse.
STOP THE ASA when on OAC
https://t.co/OSx0UKWPXe
Presenting at #ESCCongress: Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials https://t.co/bkA4ZwtbtB
Presenting at #ESCCongress: Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial https://t.co/0TVRuw8Uzf
Presented at #ESCCongress:
Among patients with myocardial infarction and a left ventricular ejection fraction of more than 40%, beta-blockers did not lead to a lower incidence of death, reinfarction, or hospitalization for heart failure than no beta-blocker therapy. Full REBOOT trial results: https://t.co/bCQMwqvcai
@escardio
Presented at #ESCCongress:
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results: https://t.co/ZCfkG7tpBI
@escardio
Original Article: Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias (POTCAST trial) https://t.co/6HUcV2CkKq
#ESCCongress | @escardio
Presented at #ESCCongress:
In patients with STEMI with cardiogenic shock, early mechanical support with a microaxial pump reduced the risk of death at 180 days, with the survival benefit persisting up to 10 years despite device-related complications. Full DanGer Shock trial results: https://t.co/BYPnBqr6vN
@escardio
Original Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET trial) https://t.co/IA8PpmkF2U
#ESCCongress | @escardio
Original Article: Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction (TARGET-FIRST trial) https://t.co/lUQPGy5Xwh
#ESCCongress | @escardio
Original Article: Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome (TACSI trial) https://t.co/dnIiQbX1qF
#ESCCongress | @escardio
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: https://t.co/ZCfkG7tpBI